Track market-moving stories before they get noisy

Bamco Inc. NY lifted its holdings in Arcellx, Inc. (NASDAQ: ACLX) by 6.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 550,236 shares of the company's stock after acquiring an additional 32,227 shares during the quarter. Bamco Inc. NY owned

On February 17, 2026, Cormorant Asset Management disclosed in a regulatory filing that it sold its entire stake in Arcellx (ACLX +0.00%), an estimated $63.63 million transaction based on last-disclosed position values.

What happenedAccording to an SEC filing dated February 17, 2026, Cormorant Asset Management sold 775,000 shares of Arcellx, fully liquidating its position. The quarter-end value of the fund’s Arcellx stake declined by $63.63 million as a result of the exit.

What else to knowThe fund’s sale of Arcellx reduced its position from 4.4% of 13F reportable AUM in the previous quarter to zero.Top holdings after the filing:NASDAQ:PRAX: $280.00 million (15.9% of AUM)NASDAQ:BBOT: $223.84 million (12.7% of AUM)NASDAQ:ABVX: $182.05 million (10.3% of AUM)NASDAQ:EYPT: $151.00 million (8.6% of AUM)NASDAQ:RAPP: $91.85 million (5.2% of AUM)As of Monday, Arcellx shares were priced at $114.51, up a staggering 60% over the past year and well outperforming the S&P 500’s roughly 19% gain in the same period.Company overviewMetricValuePrice (as of Monday)$114.51Market capitalization$6.7 billionRevenue (TTM)$22.3 millionNet income (TTM)($228.9 million)Company snapshotArcellx develops immunotherapies targeting cancer and incurable diseases, with lead candidates including CART-ddBCMA for multiple myeloma and pipeline assets for AML, MDS, and solid tumors.The company operates as a clinical-stage biotechnology company focused on research and development of cell-based therapies.It serves healthcare providers and research institutions seeking advanced oncology and hematology treatments for relapsed or refractory patient populations.Arcellx is advancing proprietary ddCAR and ARC-T cell platforms to address high unmet medical needs in relapsed or refractory cancers. The company’s pipeline includes multiple candidates targeting both hematologic malignancies and solid tumors.

What this transaction means for investorsArcellx shares are up 80% this year, and there’s one clear catalyst for that move. The company has been developing next-generation CAR-T cell therapies designed to treat cancers such as multiple myeloma. Its lead therapy, anitocabtagene autoleucel, has shown strong clinical responses and attracted the attention of larger pharmaceutical companies eager to expand their oncology pipelines.

That interest ultimately culminated in a takeover agreement from Gilead Sciences last month, valuing Arcellx at about $7.8 billion and offering shareholders $115 per share in cash plus a potential additional payment tied to future sales milestones. The deal builds on an existing 2022 collaboration between the two companies around the therapy and could accelerate development and commercialization if regulatory approvals move forward.

Still, it’s important to note this pop happened after Cormorant’s reported exit, a reminder that even smart investments can miss out due to timing flukes. What ultimately matters more is identifying companies building therapies that larger industry players ultimately want to own.

Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx. The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right (CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx’s anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029.

The tender offer, which was previously scheduled to expire at one minute after 11:59 p.m., Eastern Time, on April 2, 2026, has been extended to expire at 5:00 p.m., Eastern Time, on April 24, 2026. The transaction is anticipated to close during the second quarter of 2026, subject to the satisfaction or waiver of customary closing conditions, including the tender of a number of shares of Arcellx common stock that, together with shares already owned by Gilead, equals at least a majority of the then-outstanding Arcellx shares, the receipt of regulatory approvals and other customary offer conditions.

Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, has advised Gilead that, as of 5:00 p.m., Eastern Time, on March 31, 2026, approximately 4,389,763 shares have been validly tendered and not validly withdrawn in the tender offer, representing approximately 7.5% of the outstanding shares as of such date and time. Holders that have previously tendered their shares do not need to re-tender their shares or take any other action in response to the extension of the tender offer. Questions or requests for assistance may be directed to Innisfree M&A Incorporated, the information agent for the tender offer, by calling toll free (877) 800-5182.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Forward-Looking Statements

This communication contains forward-looking statements related to Gilead, Arcellx and the acquisition of Arcellx by Gilead that are subject to risks, uncertainties, and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of Gilead and Arcellx and members of their respective senior management teams. In some cases, forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “seek,” “may,” “plan,” “project,” “should,” “target,” “will,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, without limitation, statements regarding the transaction and related matters, prospective performance and opportunities, post-closing operations and the outlook for the companies’ businesses, including, without limitation, filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to satisfy the various closing conditions and complete the transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Arcellx’s stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of the transaction on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; the risk that, if the transaction is consummated, the businesses will not be integrated successfully and that other anticipated benefits from the transaction will not be realized; any negative effects on the existing collaboration between Arcellx and Gilead that may result from the announcement of a transaction, or the failure to complete the transaction; the risk that the milestone associated with the CVR may not be achieved and that holders of CVRs may not receive payments in respect thereof; the impact of competitive products and pricing; other business effects, including the effects of industry, economic or political conditions outside of the companies’ control; transaction costs; actual or contingent liabilities; and other risks and uncertainties detailed from time to time in the companies’ periodic reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 filed by Arcellx and the Schedule TO and related tender offer documents filed by Gilead and Ravens Sub, Inc. (“Purchaser”), a wholly owned subsidiary of Gilead. All forward-looking statements are based on information currently available to Gilead, and Gilead assume no obligation and disclaim any intent to update any such forward-looking statements.

Additional Information and Where to Find It

In connection with the proposed acquisition of Arcellx, Gilead caused Purchaser to commence a tender offer to purchase all of the outstanding shares of common stock of Arcellx. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Arcellx, nor is it a substitute for any tender offer materials that Gilead, Ravens Sub, Inc. or Arcellx has filed or will file with the SEC. A solicitation and an offer to buy securities of Arcellx is being made only pursuant to an offer to purchase and related materials that Gilead has filed with the SEC. Gilead has filed a Tender Offer Statement on Schedule TO with the SEC, and Arcellx has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. ARCELLX’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related letter of transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, have been sent to all stockholders of Arcellx at no expense to them. The Tender Offer Statement on Schedule TO, the Solicitation/Recommendation Statement on Schedule 14D-9 and other related documents are made available for free at the SEC’s web site at www.sec.gov. Additional copies may be obtained for free by contacting Gilead or Arcellx. Free copies of these materials and certain other offering documents are available from Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer. Investors and security holders of Arcellx may also obtain, free of charge, the Solicitation/Recommendation Statement on Schedule 14D-9 and other related documents that the Company has filed with or furnished to the SEC under the “Financials” section of Arcellx’s website at https://ir.arcellx.com/financials/sec-filings/default.aspx.

In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Gilead and Arcellx file annual, quarterly and current reports, proxy statements and other information with the SEC. Gilead’s and Arcellx’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

Gilead, Kite, and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

More News From Gilead Sciences, Inc.

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that all required regulatory approvals have been obtained for its previously announced acquisition of Arcellx and that Gilead has extended the expiration of the tender offer to purchase all outstanding shares of common stock of Arcellx.

On April 13, 2026, the Australian Competition and Consumer Commission (ACCC) published its decision that the acquisition of Arcellx may be put into effect, subject to expiration of a 14-calendar day waiting period. Assuming that the ACCC’s determination remains unchallenged during this waiting period, the waiting period expires at 10:00 a.m., Eastern Time, on April 27, 2026. Additionally, the relevant review period for the Austrian competition authorities has expired. Accordingly, all required regulatory approvals for the transaction have been obtained, and the “Regulatory Approvals Condition” (as defined in the Offer to Purchase, dated March 6, 2026, relating to the offer) will be satisfied upon expiration of the 14-calendar day review period pursuant to Australian competition law.

The tender offer, which was previously scheduled to expire at 5:00 p.m., Eastern Time, on April 24, 2026, has been extended to expire at 5:00 p.m., Eastern Time, on April 27, 2026, and remains subject to the satisfaction or waiver of customary closing conditions, including the tender of a number of shares of Arcellx common stock that, together with shares already owned by Gilead, equals at least a majority of the then-outstanding Arcellx shares and other customary offer conditions.

The offer remains at a purchase price of (1) $115.00 per share, net to the seller in cash, without interest, subject to any withholding tax, plus (2) one contractual contingent value right (CVR), which represents the right to receive one contingent payment of $5.00 per CVR in cash, without interest, and subject to any withholding tax, payable on March 31, 2030, subject to cumulative worldwide sales of Arcellx’s anitocabtagene autoleucel (anito-cel) product exceeding $6.0 billion on or prior to December 31, 2029.

Computershare Trust Company, N.A., the depositary and paying agent for the tender offer, has advised Gilead that, as of 4:00 p.m., Eastern Time, on April 16, 2026, approximately 10,271,823 shares have been validly tendered and not validly withdrawn in the tender offer, representing approximately 17.5% of the outstanding shares as of such date and time. Holders that have previously tendered their shares do not need to re-tender their shares or take any other action in response to the extension of the tender offer. Questions or requests for assistance may be directed to Innisfree M&A Incorporated, the information agent for the tender offer, by calling toll free (877) 800-5182.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, and cancer. In 2025, Gilead announced a planned $32 billion investment to further strengthen its U.S. footprint to power the next era of discovery, job creation and public health preparedness – while continuing to invest globally to ensure patients everywhere benefit from its scientific innovation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, Calif.

Forward-Looking Statements

This communication contains forward-looking statements related to Gilead, Arcellx and the acquisition of Arcellx by Gilead that are subject to risks, uncertainties, and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief or current expectation of Gilead and Arcellx and members of their respective senior management teams. In some cases, forward-looking statements can be identified by the use of words such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “seek,” “may,” “plan,” “project,” “should,” “target,” “will,” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, without limitation, statements regarding the transaction and related matters, prospective performance and opportunities, post-closing operations and the outlook for the companies’ businesses, including, without limitation, filings and approvals relating to the transaction; the expected timing of the completion of the transaction; the ability to satisfy the various closing conditions and complete the transaction; and any assumptions underlying any of the foregoing. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties and are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those currently anticipated due to a number of risks and uncertainties. Risks and uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include: uncertainties as to the timing of the tender offer and merger; uncertainties as to how many of Arcellx’s stockholders will tender their stock in the offer; the possibility that competing offers will be made; the possibility that various closing conditions for the transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transaction; the effects of the transaction on relationships with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; the risk that, if the transaction is consummated, the businesses will not be integrated successfully and that other anticipated benefits from the transaction will not be realized; any negative effects on the existing collaboration between Arcellx and Gilead that may result from the announcement of a transaction, or the failure to complete the transaction; the risk that the milestone associated with the CVR may not be achieved and that holders of CVRs may not receive payments in respect thereof; the impact of competitive products and pricing; other business effects, including the effects of industry, economic or political conditions outside of the companies’ control; transaction costs; actual or contingent liabilities; and other risks and uncertainties detailed from time to time in the companies’ periodic reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the Schedule 14D-9 filed by Arcellx and the Schedule TO and related tender offer documents filed by Gilead and Ravens Sub, Inc. (“Purchaser”), a wholly owned subsidiary of Gilead. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation and disclaims any intent to update any such forward-looking statements.

Additional Information and Where to Find It

In connection with the proposed acquisition of Arcellx, Gilead caused Purchaser to commence a tender offer to purchase all of the outstanding shares of common stock of Arcellx. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell securities of Arcellx, nor is it a substitute for any tender offer materials that Gilead, Ravens Sub, Inc. or Arcellx has filed or will file with the SEC. A solicitation and an offer to buy securities of Arcellx is being made only pursuant to an offer to purchase and related materials that Gilead has filed with the SEC. Gilead has filed a Tender Offer Statement on Schedule TO with the SEC, and Arcellx has filed a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the tender offer. ARCELLX’S STOCKHOLDERS AND OTHER INVESTORS ARE URGED TO READ THE TENDER OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT ON SCHEDULE 14D-9 BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT SHOULD BE READ CAREFULLY BEFORE ANY DECISION IS MADE WITH RESPECT TO THE TENDER OFFER. The Offer to Purchase, the related letter of transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement on Schedule 14D-9, have been sent to all stockholders of Arcellx at no expense to them. The Tender Offer Statement on Schedule TO, the Solicitation/Recommendation Statement on Schedule 14D-9 and other related documents are made available for free at the SEC’s website at www.sec.gov. Additional copies may be obtained for free by contacting Gilead or Arcellx. Free copies of these materials and certain other offering documents are available from Gilead by mail to Gilead Sciences, Inc., 333 Lakeside Drive, Foster City, CA 94404, attention: Investor Relations, by phone at 1-800-GILEAD-5 or 1-650-574-3000, or by directing requests for such materials to the information agent for the offer. Investors and security holders of Arcellx may also obtain, free of charge, the Solicitation/Recommendation Statement on Schedule 14D-9 and other related documents that Arcellx has filed with or furnished to the SEC under the “Financials” section of Arcellx’s website at https://ir.arcellx.com/financials/sec-filings/default.aspx.

In addition to the Offer to Purchase, the related Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Gilead and Arcellx file annual, quarterly and current reports, proxy statements and other information with the SEC. Gilead’s and Arcellx’s filings with the SEC are also available for free to the public from commercial document-retrieval services and at the website maintained by the SEC at www.sec.gov.

Gilead, Kite, and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.

More News From Gilead Sciences, Inc.

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has Arcellx, Inc. been one of those stocks this year? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.

Arcellx, Inc. is one of 890 companies in the Medical group. The Medical group currently sits at #6 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different sector groups. The average Zacks Rank of the individual stocks within the groups is measured, and the sectors are listed from best to worst.

The Zacks Rank is a proven system that emphasizes earnings estimates and estimate revisions, highlighting a variety of stocks that are displaying the right characteristics to beat the market over the next one to three months. Arcellx, Inc. is currently sporting a Zacks Rank of #2 (Buy).

Over the past three months, the Zacks Consensus Estimate for ACLX's full-year earnings has moved 1.5% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.

Based on the most recent data, ACLX has returned 76.4% so far this year. Meanwhile, stocks in the Medical group have lost about 8% on average. This means that Arcellx, Inc. is outperforming the sector as a whole this year.

Astellas Pharma Inc. (ALPMY - Free Report) is another Medical stock that has outperformed the sector so far this year. Since the beginning of the year, the stock has returned 16.1%.

Over the past three months, Astellas Pharma Inc.'s consensus EPS estimate for the current year has increased 15.2%. The stock currently has a Zacks Rank #1 (Strong Buy).

Looking more specifically, Arcellx, Inc. belongs to the Medical - Biomedical and Genetics industry, a group that includes 435 individual stocks and currently sits at #94 in the Zacks Industry Rank. On average, this group has lost an average of 0.7% so far this year, meaning that ACLX is performing better in terms of year-to-date returns.

On the other hand, Astellas Pharma Inc. belongs to the Medical - Drugs industry. This 133-stock industry is currently ranked #78. The industry has moved -0.8% year to date.

Arcellx, Inc. and Astellas Pharma Inc. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.

Rollins, Inc. in Q1 2026 saw 10% revenue growth (6.6% organic), with management reaffirming 7–8% organic and 2–3% M&A growth targets. Recent acquisitions, notably Romex for $90M, expand ROL's southern U.S. footprint and reinforce its M&A-driven growth strategy. Rollins remains a high-quality business yet trades at a premium P/E. I plan to add more shares if the stock falls to or below $50.

Key Takeaways WCN's Q1 earnings beat estimates by 3.4% and rose 8.9% year over year, lifting shares by 3.2%.Waste Connections saw revenue growth in core waste segments, driven by strong pricing gains.Waste Connections' recycling revenues fell 12.9% y/y, while the E&P waste segment jumped 24.2% y/y. Waste Connections, Inc. (WCN - Free Report) reported impressive first-quarter 2026 results, with both earnings and revenues beating the Zacks Consensus Estimate.

WCN’s first-quarter earnings of $1.23 per share beat the Zacks Consensus Estimate by 3.4% and increased 8.9% year over year. Total revenues came in at $2.4 billion, marginally surpassing the consensus estimate and rising 6.4% from the year-ago quarter.

The better-than-expected results impressed investors, as the stock has gained 3.2% since the company released results on April 22.

Over the past year, WCN shares have plummeted 17.4% compared with the industry's 7.9% decline. The Zacks S&P 500 composite has gained 32.9% during the said time frame.

WCN’s Q1 Segmental InformationThe company logged $1.7 billion in revenues from the Solid Waste Collection segment, which gained 5.4% year over year. In the Solid Waste Disposal and Transfer segment, revenues increased 6.7% from the year-ago quarter to $386.1 million. These segments improved, backed by solid core pricing.

The Solid Waste Recycling segment witnessed a 12.9% year-over-year decline in revenues to $51.6 million. For the E&P Waste Treatment, Recovery and Disposal segment, revenues totaled $179.5 million, marking a 24.2% year-over-year increase. The Intermodal and Other segment recorded $49 million in revenues, up 6.1% from the year-ago quarter.

WCN’s Operating ResultsAdjusted EBITDA in the reported quarter was $769.5 million, up 8% from the year-ago quarter. The adjusted EBITDA margin was 32.5%, up 50 basis points from the first quarter of 2025.

The company recorded an operating income of $390.2 million, which rose 7.1% from the year-ago quarter’s recorded figure.

Key Balance Sheet & Cash Flow MetricsWaste Connections exited the first quarter of 2026 with cash and cash equivalents of $112.4 million, up from $46 million in the preceding quarter. The long-term portion of debt and notes payable was $9 billion, compared with $8.8 billion in the fourth quarter of 2025.

In the reported quarter, WCN generated $546 million in cash from operating activities. The adjusted free cash flow was $245.9 million. Capital expenditure totaled $296.6 million. The company paid out $88.7 million in dividends during the quarter.

Waste Connections carries a Zacks Rank #3 (Hold) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Recent Earnings SnapshotsEquifax Inc. (EFX - Free Report) reported better-than-expected first-quarter 2026 results. EFX’s adjusted earnings per share of $1.86 beat the Zacks Consensus Estimate by 10.1% and increased 21.6% from the year-ago quarter. EFX’s revenues of $1.6 billion surpassed the consensus estimate by 2.3% and improved 14.4% year over year.

Rollins, Inc. (ROL - Free Report) posted impressive first-quarter 2026 results. ROL’s adjusted earnings of 24 cents per share matched the consensus mark and rose 9.1% from the year-ago quarter. ROL’s total revenues of $906.4 million surpassed the consensus mark by 1.3% and increased 10.2% year over year.

ROL's growth rides on tech-driven efficiency and steady acquisitions. Its rising costs, integration risks and liquidity concerns could weigh on margins.

A decade ago, Atlanta led the nation in mosquito activity—in its 6th year running, Los Angeles has firmly taken that title

, /PRNewswire/ -- As mosquito season kicks off across the U.S., Orkin's 2026 Mosquito Cities List reveals a significant shift in mosquito activity across the U.S. and where these unwelcome pests are making the biggest buzz. While Los Angeles, Chicago and New York hold the top three spots, the broader top 50 list shows mosquito activity expanding beyond traditional hotspots and reaching more regions across the country.

Data over time shows a clear geographic change. For six consecutive years, from 2015 through 2020, Atlanta held the top spot. Since 2021, Los Angeles has consistently ranked No. 1, marking a shift in the highest levels of mosquito activity. A pest issue that was once concentrated in the Southeast has evolved into a nationwide concern, with cities across every region now facing risks from this pest.

Beyond being a nuisance, mosquitoes are the deadliest animal in the world, responsible for more than 600,000 malaria-related deaths each year, according to the Centers for Disease Control and Prevention. In the U.S., they can spread serious diseases including West Nile virus, Eastern Equine Encephalitis and Zika. Additionally, mosquito-borne diseases that were once rare or uncommon in the U.S., such as dengue fever, are rising significantly, making prevention especially important as activity increases during peak season.

As part of its ongoing commitment to public health, Orkin continues its partnership with the American Red Cross through its Mosquitoes Don't Deserve a Drop campaign, helping raise awareness of mosquito-borne risks while supporting the nation's blood supply during peak season. From May to August 2026, for every mosquito control service purchased, Orkin will donate $25 to the American Red Cross, up to $250,000.

The rankings are based on the number of new residential mosquito treatments performed by Orkin from March 18, 2025, to March 18, 2026.

1. Los Angeles

26. Oklahoma City (-2) 

2. Chicago

27. Pittsburgh (+1) 

3. New York 

28. Grand Rapids, Mich. (-3)

4. Detroit (+1)

29. Norfolk, Va. (-2)

5. Atlanta (-1)

30. Cincinnati (-1)

6. Washington, D.C. (+2)

31. Richmond, Va. (-1)

7. Houston (-1)

32. St. Louis (+15)

8. Dallas (-1)

33. Flint, Mich. (-2)

9. Cleveland

34. Boston (+6)

10. Denver

35. Knoxville, Tenn. (+1)

11. Raleigh, N.C. (+2)

36. West Palm Beach, Fla. (+6)

12. Charlotte, N.C. (+2)

37. Tulsa, Okla. (-5)

13. Minneapolis (+6)

38. Albuquerque, N.M. (-3)

14. Philadelphia (-3)

39. Sacramento, Calif. (new)

15. Indianapolis (+1)

40. Phoenix (new)

16. Tampa, Fla. (+2)

41. San Antonio (-4)

17. Miami (-5)

42. Cedar Rapids, Iowa (-9)

18. San Francisco (-3) 

43. Traverse City, Mich. (new)

19. Orlando, Fla. (-2)

44. Hartford, Conn. (+1)

20. Columbus, Ohio (+3)

45. San Diego (-6)

21. Greenville, S.C. (+1)

46. Columbia, S.C. (-5)

22. Baltimore (-2)

47. Springfield, Ill. (new)

23. Milwaukee (+15) 

48. Memphis, Tenn. (-14)

24. Seattle (+2)

49. Greenville, N.C. (new)

25. Nashville, Tenn. (-4) 

50. Greensboro, N.C. (-5)

"Over the past decade, we've seen mosquito activity expand beyond traditional hotspots and become a nationwide concern," said Shannon Sked, Orkin entomologist. "While major cities continue to experience consistent pressure, emerging trends—especially in the Midwest—show how shifting climate conditions and the expanding range of the yellow fever mosquito are creating new hotspots across the country."

Midwestern cities continue to see some of the fastest growth year-over-year, with Milwaukee jumping 15 spots to No. 23 and Minneapolis climbing six spots to No. 13. At the same time, some historically high-ranking cities saw declines, with Miami and Greensboro, N.C. each dropping five spots. Changes like these underscore how environmental factors, including the spread of species like the yellow fever mosquito (Aedes aegypti), are reshaping mosquito pressures across the country.

Several new cities appeared on this year's list, including first-time entries Traverse City, Mich., Greenville, N.C. and Springfield, Ill., alongside returning cities like Sacramento, Calif. and Phoenix. Together, they highlight how mosquito activity is expanding into regions not traditionally associated with high levels of mosquito pressure. 

To help reduce mosquito activity, Orkin recommends using the acronym BITE to remember key prevention steps:

Block access to skin by wearing long sleeves and pants, as well as CDC-recommended repellents. Install tight-fitting screens on windows and doors. Trim shrubs, grass and other vegetation to reduce mosquito resting areas. Eliminate standing water, which is a breeding ground for mosquitoes. For more mosquito facts and prevention tips, visit Orkin.com.

About Orkin, LLC  
Founded in 1901, Atlanta-based Orkin has been shaping the pest control industry for 125 years, providing protection against termite damage, rodents and insects through its commitment to scientific knowledge and unmatched training. From its earliest days to today, Orkin's innovative spirit continues to define the future of pest management. 

Orkin is dedicated to protecting the places where we live, work and play by helping prevent and control pests and educating consumers about the potential health risks they pose. Guided by a service-first mission to deliver peace of mind, Orkin Pros are trusted professionals who embody the company's values of safety, integrity, professionalism, empathy and innovation. Since 2020, Orkin has partnered with the American Red Cross® to raise awareness about mosquito-borne health threats while supporting the nation's blood supply through monetary contributions and blood donations.

Orkin has more than 400 owned and operated branch offices and nearly 50 franchises in the U.S. The company also has international franchises and subsidiaries in Canada, Europe, Central America, South America, the Caribbean, the Middle East, Asia, the Mediterranean, Africa and Mexico. Learn more about careers at Orkin here.

Visit Orkin.com for additional information. Orkin is a wholly-owned subsidiary of Rollins Inc. (NYSE: ROL). Follow us on Facebook, Instagram, TikTok and LinkedIn.  

SOURCE Orkin, LLC

, /PRNewswire/ -- Rollins, Inc. (NYSE:ROL) ("Rollins" or the "Company"), a premier global consumer and commercial services company, will hold its 2026 Investor and Analyst Conference on Thursday, May 14, at 9 a.m. Eastern Time.

A webcast of the event will be available by logging onto the Rollins, Inc. website at www.rollins.com/investors/events-presentations. The webcast will be available approximately three hours after the event has concluded.

About Rollins, Inc.:

Rollins, Inc. (ROL) is a premier global consumer and commercial services company. Through its family of leading brands, the Company and its franchises provide essential pest control services and protection against termite damage, rodents, and insects to more than 2.8 million customers in North America, South America, Europe, Asia, Africa, and Australia, approximately 22,000 employees from more than 850 locations. Rollins is parent to Aardwolf Pestkare, Clark Pest Control, Crane Pest Control, Critter Control, Fox Pest Control, HomeTeam Pest Defense, Industrial Fumigant Company, McCall Service, MissQuito, Northwest Exterminating, OPC Pest Services, Orkin, Orkin Australia, Orkin Canada, PermaTreat, Safeguard, Saela Pest Control, Trutech, Waltham Services, Western Pest Services, and more. You can learn more about Rollins and its subsidiaries by visiting www.rollins.com.

Investor Contact:
[email protected]
(404) 888-2000

SOURCE Rollins, Inc.

, /PRNewswire/ -- Rollins, Inc. (NYSE: ROL) ("Rollins" or the "Company"), a premier global consumer and commercial services company, today highlighted its strategy for driving sustainable, long-term value creation through a resilient, capital-light business model, a durable organic growth engine, disciplined M&A, and a balanced approach to capital allocation.

The Company emphasized its track record of consistent performance across economic cycles, including 25 consecutive years of revenue and adjusted EBITDA growth and approaching its 100th consecutive quarter of revenue growth, supported by recurring customer relationships and ongoing investments in modernization and operating discipline.

Strong market with expansion opportunities

Rollins operates in a highly attractive pest control market estimated at over $20 billion, supported by a number of secular tailwinds and evolving consumer preferences with the opportunity for continued growth as adoption expands. Durable organic growth engine to drive 7-8% organic growth

Management reiterated its medium-term goal of 7-8% organic growth, supported by five primary drivers: market growth, pricing, recurring revenue, commercial growth, and ancillary services. M&A opportunity of 2-3% with upside potential

Rollins views M&A as an important complement to organic growth and is targeting 2-3% annual growth from acquisitions, with upside potential supported by a large, fragmented market and an expanding pipeline of opportunities. Margin and earnings power

Management reaffirmed a focus on strong incremental margins and sustainable double-digit earnings growth, supported by multiple operating levers alongside continued revenue expansion. Cash flow compounding in the mid-teens and balanced capital allocation

Rollins emphasized its capital-light model and strong cash generation and reiterated its objective to convert free cash flow above 100%. Medium-term outlook

The Company reiterated its growth algorithm of 7-8% organic growth, 2-3% growth from M&A, 30-35% incremental margin from the core business, and free cash flow conversion above 100% aimed at delivering consistent double-digit revenue, earnings, and cash-flow growth. See the Company's SEC filings for definitions of our non-GAAP metrics, how they are calculated, and reconciliations to their most directly comparable GAAP metric.

Executive Commentary

"Our company compounds cash flow by acquiring and growing market-leading pest control businesses. We find the very best stand-alone businesses, fund their growth, and generate attractive returns on our investments. We do this with a people-first, customer-centric mindset that is the foundation on which our financial engine is built. This is what we've done for decades and what we will continue to do as we live out the next chapter in our Company's success story," said Jerry Gahlhoff, President and Chief Executive Officer.

"With a highly recurring, capital-light model and a proven track record of consistent performance through multiple economic cycles, we believe our value creation algorithm remains both compelling and sustainable," said Ken Krause, Executive Vice President and Chief Financial Officer.

Forward-Looking Statements

This release as well as other written or oral statements by the Company may contain "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current opinions, expectations, intentions, beliefs, plans, objectives, assumptions and projections about future events and financial trends affecting the operating results and financial condition of our business. Although we believe that these forward-looking statements are reasonable, we cannot assure you that we will achieve or realize these plans, intentions, or expectations. Generally, statements that do not relate to historical facts, including statements concerning possible or assumed future actions, business strategies, events or results of operations, are forward-looking statements. The words "believe," "continue," "could," "estimate," "expect," "intend," "may," "might," "plan," "possible," "potential," "predict," "should," "will," "would," and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking.

Forward-looking statements in this release include, but are not limited to, statements regarding: expectations with respect to our financial and business performance; expectations related to acquisitions, including expected M&A revenue growth contribution of 2–3%; our expected growth, including medium-term targets for organic revenue growth of 7–8%, adjusted incremental EBITDA margins of approximately 30–35%, free cash flow conversion in excess of 100%, and double-digit earnings and free cash flow growth; expectations regarding market growth; focus on margins supported by operating levers and continued revenue expansion; a balanced capital allocation strategy. These forward-looking statements, including the medium-term targets discussed herein, are objectives and targets only and should not be regarded as representations or guarantees that such results will be achieved. Actual results may differ materially from these targets. 

These forward-looking statements are based on information available as of the date of this presentation, and current expectations, forecasts, and assumptions, and involve a number of judgments, risks and uncertainties. Important factors could cause actual results to differ materially from those indicated or implied by forward-looking statements including, but not limited to, those set forth in the sections entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, and may also be described from time to time in our future reports filed with the SEC.

Accordingly, forward-looking statements should not be relied upon as representing our views as of any subsequent date, and we do not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date they were made, whether as a result of new information, future events or otherwise, except as maybe required by law.

The Company has not reconciled its forward-looking adjusted incremental EBITDA margin, free cash flow conversion, or other forward-looking non-GAAP financial measures to the most directly comparable GAAP measures because the Company cannot predict with reasonable certainty the ultimate outcome or timing of certain significant items without unreasonable effort. These items include, but are not limited to, acquisition-related expenses, adjustments to the fair value of contingent consideration, restructuring charges, gains or losses on the disposition of assets or businesses, and other unusual or infrequent items. These items are uncertain, depend on various factors, and could have a material impact on GAAP reported results for the applicable periods. A reconciliation of these forward-looking non-GAAP measures is therefore not available without unreasonable effort.

About Rollins, Inc.

Rollins, Inc. (ROL) is a premier global consumer and commercial services company. Through its family of leading brands, the Company and its franchises provide essential pest control services and protection against termite damage, rodents, and insects to more than 2.8 million customers in North America, South America, Europe, Asia, Africa, and Australia, approximately 22,000 employees from more than 850 locations. Rollins is parent to Aardwolf Pestkare, Clark Pest Control, Crane Pest Control, Critter Control, Fox Pest Control, HomeTeam Pest Defense, Industrial Fumigant Company, McCall Service, MissQuito, Northwest Exterminating, OPC Pest Services, Orkin, Orkin Australia, Orkin Canada, PermaTreat, Safeguard, Saela Pest Control, Trutech, Waltham Services, Western Pest Services, and more. You can learn more about Rollins and its subsidiaries by visiting www.rollins.com.

Investor Contact:
[email protected]  
(404) 888-2000

SOURCE Rollins, Inc.

It has been about a month since the last earnings report for Rollins (ROL - Free Report) . Shares have lost about 7% in that time frame, underperforming the S&P 500.

But investors have to be wondering, will the recent negative trend continue leading up to its next earnings release, or is Rollins due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the latest earnings report in order to get a better handle on the important catalysts.

Rollins Q1 Earnings Beat EstimatesRollin Inc. reported impressive first-quarter 2026 results, with earnings meeting the Zacks Consensus Estimate and revenues beating the same.

ROL’s adjusted earnings per share of 24 cents matched the consensus mark and rose 9.1% year over year. Total revenues were $906.4 million, which beat the consensus mark by 1.3% and increased 10.2% from the year-ago quarter.

Quarterly Details of ROLResidential revenues of the pest control company increased 9.3% year over year to $389.5 million and beat the Zacks Consensus Estimate of $384.4 million. Commercial revenues rose 9.6% year over year to $311.7 million and surpassed the consensus estimate of $304.5 million. Termite and ancillary revenues were $195.4 million, representing a 13.5% year-over-year increase.

Adjusted operating income was $152.8 million, up 4% year over year, while adjusted operating margin decreased 100 basis points to 16.9%.

Adjusted EBITDA of $179.5 million jumped 4.4% year over year. The adjusted EBITDA margin of 19.8% decreased 110 basis points year over year.

Key Balance Sheet & Cash Flow FiguresRollins exited the quarter with cash and cash equivalents of $116.5 million, up from $100 million in the fourth quarter of 2025. Long-term debt at the end of the quarter was $486.6 million compared with $486.1 million at the end of the fourth quarter of 2025.

The company generated $118.4 million in cash from operating activities in the quarter and the capital expenditure was $7.1 million. Free cash flow came in at $111.2 million. ROL paid dividends worth $87.9 million in the quarter.

How Have Estimates Been Moving Since Then?It turns out, estimates revision have trended upward during the past month.

VGM ScoresCurrently, Rollins has a average Growth Score of C, a grade with the same score on the momentum front. Charting a somewhat similar path, the stock was allocated a score of D on the value side, putting it in the bottom 40% for value investors.

Overall, the stock has an aggregate VGM Score of C. If you aren't focused on one strategy, this score is the one you should be interested in.

OutlookEstimates have been trending upward for the stock, and the magnitude of this revision looks promising. Notably, Rollins has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.

, /PRNewswire/ -- Rollins, Inc. (NYSE: ROL), a premier global consumer and commercial services company, today announced that members of management will present at the following events:

William Blair 46th Annual Growth Stock Conference at the Loews Hotel, Chicago, Illinois, on Wednesday, June 3rd from 1:00 p.m. – 1:30 p.m. E.T.

Baird 2026 Global Consumer, Technology & Services Conference at the Intercontinental New York Barclay, New York, on Thursday, June 4th from 9:05 a.m. – 9:35 a.m. E.T.

These events will be webcast live and can be accessed at https://www.rollins.com/investors/events-presentations. Following the presentations, a replay will be available for 180 days at the link listed above, under the "Events and Presentations" menu. Please note that the schedule above is subject to change.

About Rollins, Inc.

Rollins, Inc. (ROL) is a premier global consumer and commercial services company. Through its family of leading brands, the Company and its franchises provide essential pest control services and protection against termite damage, rodents, and insects to more than 2.8 million customers in North America, South America, Europe, Asia, Africa, and Australia, with approximately 22,000 employees from more than 850 locations. Rollins is parent to Aardwolf Pestkare, Clark Pest Control, Crane Pest Control, Critter Control, Fox Pest Control, HomeTeam Pest Defense, Industrial Fumigant Company, McCall Service, MissQuito, Northwest Exterminating, OPC Pest Services, Orkin, Orkin Australia, Orkin Canada, PermaTreat, Safeguard, Saela Pest Control, Trutech, Waltham Services, Western Pest Services, and more. You can learn more about Rollins and its subsidiaries by visiting www.rollins.com.

Investor Contact:
[email protected]  
(404) 888-2000

SOURCE Rollins, Inc.

Rollins, Inc. (ROL) 2026 Baird Global Consumer, Technology & Services Conference June 4, 2026 9:35 AM EDT

Company Participants

Lyndsey Burton - Vice President of Investor Relations
William Harkins - Chief Accounting Officer

Conference Call Participants

Justin Hauke - Robert W. Baird & Co. Incorporated, Research Division

Presentation

Justin Hauke
Robert W. Baird & Co. Incorporated, Research Division

Okay. Good morning, everyone. I'm Justin Hauke. I'm the senior analyst covering facility and industrial services. And presenting next, we have the pleasure of hosting Rollins, which is the largest pest elimination company in the United States and then probably beyond that, too. So -- but yes, so presenting is going to be -- we've got Lyndsey Burton, who leads IR, and then Will Harkins, who is the very newly appointed Chief Financial Officer, but not a stranger to the company.

So I'll let you guys do some little introductory remarks, and then we'll go into Q&A, a small room. So I've got questions, but when we open it up, we can also just take questions from the audience. So I'll let you guys start.

Lyndsey Burton
Vice President of Investor Relations

Sure. Well, thanks for having us. It's great to be here. Yes. So we are -- it's an honor to be here representing our 20,000-plus teammates around the world. We are a provider of essential services across a number of different offerings in both the residential and commercial space. Fantastic business model, a fantastic culture with a very long history and a pretty exceptional track record of performance. We -- 100 -- nearing in on 100 straight quarters of growth, 75% recurring business. And at the end of the day, I think what we're really proud of is just how our teammates continue to evolve. Our portfolio of brands is pretty exceptional. It's been built and curated very thoughtfully over many, many years. And so we think that's a very distinct competitive advantage.

, /PRNewswire/ -- The Board of Directors of Truist Financial Corporation (NYSE: TFC) declared a regular quarterly cash dividend of $0.52 per common share, payable on June 1, 2026, to shareholders of record at the close of business on May 8, 2026.

The Board also declared regular cash dividends on the following series of preferred stock:

Series of Preferred Stock

Dividend per
Share

Dividend per
Depositary
Share

Record

Date

Payment

Date

Series I Non-Cumulative
Perpetual Preferred Stock
(CUSIP 89832Q810)

$1,128.80950(1)

$0.28220(1)

May 8

Jun. 15

Series J Non-Cumulative
Perpetual Preferred Stock
(CUSIP 86800XAA6)

$1,157.87894(1)

$11.57879(1)

May 8 (2)

Jun. 15

Series M Non-Cumulative
Perpetual Preferred Stock

(CUSIP 89832QAC3)

$2,562.50

$25.625

May 8

Jun. 15(3)

Series O Non-Cumulative
Perpetual Preferred Stock
(CUSIP 89832Q745)

$328.125

$0.328125

May 8

Jun. 1

Series R Non-Cumulative
Perpetual Preferred Stock
(CUSIP 89832Q695)

$296.875

$0.296875

May 8

Jun. 1

Notes:

(1)

In the table, dividends per share and dividends per depositary share for Series I and Series J are rounded to the hundred-thousandths position for the convenience of the reader. 

(2)

In accordance with the Amended and Restated Declaration of Trust of SunTrust Preferred Capital I, the record date for the Preferred Purchase Securities representing fractional interests in shares of Series J preferred stock will be May 31, 2026.

(3)

Dividends per share and dividends per depositary share for Series M are declared and paid semiannually.

About Truist
Truist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist is a top-10 commercial bank with total assets of $549 billion as of March 31, 2026. Truist Bank, Member FDIC. Equal Housing Lender. Learn more at Truist.com.

SOURCE Truist Financial Corporation

Also from this source

, /PRNewswire/ -- Truist Bank (NYSE: TFC) today announced it will redeem all $1,250,000,000 principal amount outstanding of its fixed-to-floating rate senior notes due May 20, 2027, (CUSIP 89788JAE9) on the redemption date of May 20, 2026.

The redemption price for the senior notes will be equal to 100% of the principal amount plus accrued and unpaid interest to, but excluding, the redemption date. Interest on the senior notes will cease to accrue on and after the redemption date.

Payment of the redemption price for the senior notes will be made through the facilities of The Depository Trust Company.

About Truist
Truist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist is a top-10 commercial bank with total assets of $549 billion as of March 31, 2026. Truist Bank, Member FDIC. Equal Housing Lender. Learn more at Truist.com.

SOURCE Truist Financial Corporation

Key Takeaways JPMorgan's scale and diversification give it the edge over Truist in an uncertain banking environment.As of March 31, 2026, JPMorgan had $4.9T assets, $2.7T deposits and $1.5T loans.Truist is chasing a recovery via efficiency, branch optimization and expansion into higher-growth markets. JPMorgan (JPM - Free Report) and Truist Financial (TFC - Free Report) offer two very different banking stories. JPMorgan is the largest U.S. bank, with unmatched scale, global reach and broad business diversification. Truist, meanwhile, is one of the major regional banking players in the United States, with a strong presence in attractive markets across the Southeast and Mid-Atlantic.

Now, the question arises whether JPM’s size and stability make it the better choice, or TFC’s regional strength and potential recovery story offer more upside.

Scale Advantage: JPMorgan’s Clear Lead Over TruistJPMorgan’s scale is its biggest advantage, providing a large deposit base, strong brand, major technology spending power and leading positions across consumer and institutional banking. Its investments in digital platforms, risk management, data analytics and innovation strengthen its edge, while its global reach and diversified operations help offset weakness in any single business line.

Truist, by contrast, has a more concentrated business model. Its regional focus can be a strength as it allows the bank to deepen relationships in core markets. However, it also means Truist is more exposed to regional economic trends, deposit competition and localized credit pressures. Compared with JPMorgan, it has less diversification and a smaller margin for error.

JPM vs. TFC: Stability and Balance Sheet StrengthJPMorgan stands out for its financial resilience. The bank has a long record of navigating difficult market environments, helped by strong risk management, a deep deposit base and consistent profitability. Its capital strength and liquidity position give it the flexibility to absorb credit losses, meet regulatory requirements and continue investing in growth. As of March 31, 2026, it had total assets of $4.9 trillion, with $1.5 trillion in loans and $2.7 trillion in deposits.

Truist has been working to strengthen its balance sheet and improve profitability. Like many regional banks, it faced pressure from higher deposit costs, cautious loan growth and investor concerns about commercial real estate and credit quality. Management’s ability to control costs, protect capital and stabilize margins will be central to the bank’s investment case. As of March 31, 2026, Truist’s total assets were $549 billion, loans and leases were $329.2 billion, and deposits were $404.1 billion.

While Truist remains a significant banking franchise, it does not offer the same level of perceived safety as JPMorgan. Its path forward depends more heavily on execution and improving operating trends.

JPMorgan & Truist’s Growth ProspectsJPMorgan has several long-term growth drivers. These include expansion in wealth management, market-share gains in commercial banking, continued strength in credit cards and payments, digital banking investments and a potential rebound in investment banking activity. The bank’s ability to attract clients across consumer, corporate and institutional segments supports steady growth over time.

Another advantage is that JPMorgan can use periods of industry disruption to gain share. When smaller banks face pressure, large banks with strong balance sheets often benefit from customer inflows and stronger competitive positioning. This gets reflected in its earnings power. The Zacks Consensus Estimate for JPMorgan's 2026 earnings suggests a 10.2% rise on a year-over-year basis, while 2027 earnings are expected to grow at a rate of 5.1%.

JPM’s Earnings Estimates
 

Image Source: Zacks Investment Research

Truist’s growth story is more tied to recovery and self-help. The bank is focused on improving efficiency, optimizing its branch network, strengthening digital capabilities and expanding in its core markets. Last August, the company announced plans to expand into higher-growth markets and is focused on adding talent, building pipelines and strengthening digital capabilities. If these are successfully executed, Truist will be able to deliver better profitability.

Though Truist’s growth outlook is dependent on expense discipline, deposit stability, loan demand and a healthier rate environment, analysts seem to be bullish on prospects. The Zacks Consensus Estimate for TFC's 2026 earnings suggests a 14.4% increase on a year-over-year basis, while 2027 earnings are expected to rise 13.3%.

TFC’s Earnings Estimates
 

Image Source: Zacks Investment Research

JPM or TFC: Dividend and Shareholder ReturnsBoth JPMorgan and Truist appeal to income-focused investors, but the quality of the dividend story differs.

JPMorgan’s dividend is backed by broad earnings power, capital flexibility and a strong franchise. The bank has the capacity to return capital to shareholders while still investing in growth and meeting regulatory demands. Over the past five years, the company has raised dividends six times, with an annualized growth rate of 10.81%. It has a share repurchase program worth $50 billion in place. As of March 31, 2026, almost $25.7 billion remained available.

Truist offers an attractive dividend yield, but hasn’t raised its dividends for several years now. The company pays 52 cents per share as a quarterly dividend. In 2025, it authorized a new $10 billion share repurchase program with no expiration. As of March 31, 2026, $8.9 billion worth of authorization remained available. Management is targeting about $5 billion of share repurchases in 2026.

Dividend Yield
 

Image Source: Zacks Investment Research

Truist offers a higher dividend yield compared with JPMorgan, but investors will likely focus on dividend sustainability, capital priorities and the pace of earnings growth. Though a higher yield can be appealing to income investors, it should not be the sole focus before investing.

Key Risks for JPMorgan & TruistFor JPMorgan, the main risks include tougher regulation, higher capital requirements, economic weakness, rising credit losses and cyclicality in investment banking and markets-related revenue. Its size also attracts regulatory and political scrutiny.

For Truist, the key risks are more execution-oriented. These include regional banking pressure, deposit cost challenges, commercial real estate exposure, weak loan growth and slower-than-expected profitability improvement. If management fails to deliver on efficiency and capital goals, the stock could remain under pressure.

Valuation Analysis: JPMorgan Trades at a Premium vs. TruistIn terms of valuation, JPM is currently trading at a 12-month forward price-to-earnings (P/E) of 13.15X, while the TFC stock is currently trading at a 12-month forward P/E of 9.81X. 

P/E F12M
 

Image Source: Zacks Investment Research

JPMorgan commands a premium valuation because of its scale, consistency and best-in-class reputation. Investors are usually willing to pay more for a bank that offers stronger earnings visibility and lower relative risk. On the other hand, Truist may look cheaper on valuation, but that discount reflects the challenges it faces. The stock could offer upside if management improves efficiency, stabilizes margins and restores stronger earnings momentum.

JPMorgan or Truist: Which Bank Stock Has the Edge?In the past three months, shares of JPMorgan have lost 0.7%, while Truist declined 10.3%. 

JPM & TFC Price Performance
 

Image Source: Zacks Investment Research

In terms of investor sentiment, JPMorgan has the clear edge. Its scale, diversified revenues, earnings resilience and strong risk management make it better positioned in an uncertain banking environment.

Truist offers appeal through its regional presence, valuation discount and expansion efforts, but it carries higher execution risk. While Truist may suit investors seeking recovery-driven upside, JPMorgan’s stability, consistency and growth potential make it the stronger choice.

At present, JPM and TFC carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Resources Investor Relations Journalists Agencies Client Login Send a Release News Products Contact , /PRNewswire/ -- Truist Financial Corporation (NYSE: TFC) today announced that Chief Financial Officer Mike Maguire will speak at the Morgan Stanley U.S. Financials Conference on Tuesday, June 9, 2026, at 11:15 a.m. ET.

A live audio webcast will be available on the day of the conference at ir.truist.com under Events & Presentations. A replay of the webcast will be available on the website for 30 days.

About Truist
Truist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist is a top 10 commercial bank with $549 billion as of March 31, 2026. Truist Bank, Member FDIC. Equal Housing Lender. Learn more at Truist.com.

SOURCE Truist Financial Corporation

Also from this source

Truist Financial Corporation (TFC) Presents at Bernstein 42nd Annual Strategic Decisions Conference Transcript

Despite some modest operational challenges, Truist Financial has been a solid performer since I upgraded it to Buy nearly a year ago, returning around 15%. Net interest income is tracking weaker than expected amid tepid volume growth, but market-facing operations and non-interest income have been brighter. TFC is still sitting on a healthy level of surplus capital, and with retained earnings improving, that's led to a step-up in buyback spending, supporting EPS growth.

Key Takeaways BAC is viewed as well-positioned for 2026 upside due to scale, diversification and earnings growth.BAC expects NII growth in the upper end of 6-8% in 2026, supported by loans and stabilizing funding costs.TFC offers a discounted valuation, but higher expenses may limit near-term operating leverage. Bank of America (BAC - Free Report) and Truist Financial Corporation (TFC - Free Report) operate in the same banking landscape but offer investors very different risk-reward profiles. Bank of America stands out for its global scale, diversified revenue streams and strong deposit franchise, positioning it to benefit from improving capital markets activity, easing funding pressures and a more favorable rate backdrop.

Truist, alternatively, offers the appeal of a regional bank recovery story, with the upside tied to cost discipline, balance-sheet repositioning and margin stabilization.

Both banks are investing heavily in technology, data analytics and artificial intelligence (AI) to improve efficiency and deepen customer relationships. However, they differ meaningfully in size, business mix and diversification.

With consumer spending remaining resilient, loan demand improving, investment banking (IB) activity recovering and AI-driven productivity tools gaining traction, the key question is: which stock among BAC and TFC is better-positioned to capitalize on these trends and deliver stronger upside in 2026?

The Case for BACBank of America, the second-largest bank in the United States, is well-positioned for near-term improvement in net interest income (NII), supported by loan growth, fixed-rate asset repricing and stabilizing funding costs. From 2020 to 2025, the company’s NII grew at a compound annual growth rate (CAGR) of 6.7%, with the momentum continuing in the first quarter of 2026. Management expects fully taxable-equivalent NII to increase in the upper end of the 6-8% range this year.

BAC’s IB business has shown a meaningful recovery after a weak 2022 and 2023, when IB fees in the Global Banking segment declined 45.7% and 2.4%, respectively. The business rebounded in 2024 and 2025, with fees rising 31.4% and 8.4%, respectively. With global merger and acquisition activity improving and the company maintaining a healthy deal pipeline, BAC is expected to continue benefiting from solid growth in IB fees.

The company’s trading business has also improved since 2022. In the first quarter of 2026, sales and trading revenues, excluding net DVA, rose 12% year over year. However, given the volatile nature of capital markets, trading revenues can fluctuate significantly and may create earnings variability even when overall performance remains favorable.

Bank of America continues to focus on organic growth by expanding both physical and digital presence. This strategy is aimed at strengthening customer relationships, entering new markets and supporting long-term NII growth. By 2027, the company plans to open more than 150 financial centers. At the same time, the increased adoption of digital tools such as Zelle and its AI-powered assistant Erica is helping BAC boost customer engagement and cross-sell products, including mortgages, auto loans and credit cards.

The Case for TFCCompared with Bank of America, Truist has a more regionally focused business model and is relatively less exposed to interest rate cycles and capital markets volatility. Since selling its insurance subsidiary in 2024, the company has been working to strengthen its balance sheet, reposition its portfolio and expand more stable sources of non-interest income.

In August 2025, TFC announced a long-term growth plan aimed at deepening its presence in attractive U.S. markets. The plan includes opening 100 new branches, renovating more than 300 existing locations in high-growth cities by 2030 and investing in its business banking ecosystem.

Truist is also focusing on wealth management and IB as key drivers of fee income. While total non-interest income declined in 2022 and 2024 due to large securities losses, non-interest income, excluding those losses, saw a six-year (2019-2025) CAGR of 1.9%. A broader recovery in trading and IB activity could further support fee revenue growth.

On the interest income side, Truist’s NII saw a five-year (2020-2025) CAGR of 1.1%, helped by solid loan demand and higher rates, with the momentum continuing in the first quarter of 2026. For 2026, management expects average loan growth of 3-4% and NII growth of 2-3%, assuming stable policy rates.

However, Truist’s growth strategy comes with cost pressure. As the company expands its branch network, upgrades technology and adds talent to strengthen its commercial banking business, expenses are likely to remain elevated. Management expects GAAP expenses to rise 1.75% in 2026, which could limit near-term operating leverage compared with Bank of America’s scale-driven efficiency.

BAC & TFC: Price Performance, Valuation & Other ComparisonsOver the past three months, TFC and BAC shares have risen 5.2% and 12.4%, respectively. Hence, in terms of price performance, Bank of America has a clear edge over Truist.

3-Month Price Performance
Image Source: Zacks Investment Research

In terms of valuation, Truist is currently trading at a 12-month forward price-to-earnings (P/E) of 10.30X. Bank of America, in contrast, is trading at a 12-month forward P/E of 11.40X.

Therefore, TFC is trading at a discount compared with BAC.

P/E F12M
Image Source: Zacks Investment Research

Bank of America’s return on equity (ROE) of 11.49% is way higher than Truist’s 9.55%. This reflects BAC’s efficient use of shareholder funds in generating profits.

ROE
Image Source: Zacks Investment Research

How Do Earnings Estimates Compare for TFC & BAC?The Zacks Consensus Estimate for BAC's 2026 and 2027 earnings indicates 16.8% and 14.2% year-over-year growth, respectively. In the past week, the company’s earnings estimates for both years have been unchanged.

BAC Estimate Revision Trend
Image Source: Zacks Investment Research

The Zacks Consensus Estimate for TFC’s 2026 and 2027 earnings indicates rallies of 14.4% and 13.3%, respectively. Earnings estimates for both years have been unchanged over the past seven days.

TFC Estimate Revision Trend
Image Source: Zacks Investment Research

BAC or TFC: Which Bank Is Positioned for Better Upside?Bank of America seems well-positioned to capitalize on the current interest rate environment through its scale, diversified income streams and branch expansion strategy. Its robust earnings growth outlook, superior ROE and impressive capital distribution activities signal financial strength and shareholder value creation. The company’s digital innovations and cross-selling opportunities also provide a long-term competitive advantage.

Truist Financial, though less sensitive to rate shifts, presents relatively modest earnings growth. Its discounted valuation and expansion strategy may appeal to value investors, but overall, Bank of America appears the stronger long-term bet right now.

Currently, both TFC and BAC carry a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Move builds on Grandbridge's established Primary and Special Servicing Platform

, /PRNewswire/ -- Grandbridge Real Estate Capital, a wholly owned subsidiary of Truist Bank and Truist Bank's parent company, Truist Financial Corporation (NYSE: TFC), today announced the launch of its Master Servicing platform. This marks a significant expansion in Grandbridge's commercial mortgage servicing capability and further strengthens Truist as a national leader in commercial real estate.

The ratings position Grandbridge among a select group of institutions with the scale and expertise to oversee complex commercial mortgage-backed securities (CMBS) transactions.

Grandbridge secured Master Servicer ratings after completing the review process with all major rating agencies, building on its established primary and special servicing operations.

The reviews confirm that Grandbridge has the controls, people, and infrastructure to manage commercial mortgage loans through the full life cycle – from origination and financing to long-term administration and servicing.

"This represents a significant expansion of our business model as we continue our journey to be a full-service provider of solutions to the commercial real estate sector," said Kathy Farrell, head of Truist Asset Finance. "Master servicing deepens how we support real estate owners across the full life cycle of their assets while ensuring the success of projects that strengthen communities and improve lives."

Grandbridge is a full-service real estate lending platform that originates, finances, and services commercial and multifamily real estate loans and portfolios nationwide.

Master servicing plays a critical role in CMBS transactions by helping provide consistent administration, reporting, cash flow oversight, and portfolio performance support across large pools of commercial mortgage loans.

"This achievement demonstrates the discipline and long-term focus that define our business," said Adam Oates, head of Grandbridge. "Earning these ratings reinforces the confidence clients and investors place in us and reflects our purpose-driven approach to serving them every day."

Grandbridge has served as a primary servicer of commercial mortgage loans for more than 30 years, currently servicing CMBS, CRE CLO, Life Company, Bridge, HUD, and Agency loans. The master servicing operation is supported by Truist's balance sheet, liquidity, technology, and risk framework, providing additional assurance to investors and counterparties as market conditions evolve.

This milestone underscores Truist's commitment to delivering best-in-class capabilities to clients across industries and its ongoing investment in its Wholesale Banking platform, which provides comprehensive solutions to commercial, corporate, institutional and high-net-worth clients.

About Truist
Truist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of the high-growth markets in the U.S. and offers a wide range of products and services through wholesale and consumer businesses, including consumer and small business banking, commercial and corporate banking, investment banking and capital markets, wealth management, payments, and specialized lending businesses. Truist Bank, a wholly owned subsidiary of Truist Financial Corporation, is a top 10 commercial bank with total assets of $549 billion as of March 31, 2026. Truist Bank, Member FDIC. Equal Housing Lender. Learn more at Truist.com.

About Grandbridge Capital
Headquartered in Charlotte, NC, Grandbridge Real Estate Capital LLC, a subsidiary of Truist Bank, facilitates financing for permanent commercial and multifamily real estate loans; services loan portfolios; and provides asset and portfolio management through its broad investor base that includes insurance companies, CMBS investors, pension fund advisors, commercial banks and capital markets investors. The company is a Freddie Mac Optigo® lender, a Fannie Mae DUS® lender and an approved FHA MAP lender. With a current servicing portfolio of $26.7 billion, Grandbridge maintains ratings from all five major rating agencies, and services loan portfolios and provides asset and portfolio management nationwide for all capital providers including Freddie Mac, Fannie Mae, Ginnie Mae, insurance companies, banks and more than 250 securitizations.

SOURCE Truist Financial Corporation

In collaboration with MIT Solve, Truist Foundation will provide more than $1 million in grants and in-kind services to nonprofits to help workers navigate AI-driven changes

, /PRNewswire/ -- Truist Foundation today announced the launch of its fourth Inspire Awards, a capacity-building grant program for nonprofit organizations across the markets Truist Bank serves. This year's challenge aligns to Truist Foundation's focus on creating career pathways to economic mobility and aims to upskill adult workers navigating rapid technological change in the era of artificial intelligence (AI).

Lynette Bell discusses open application period for Truist Foundation's fourth Inspire Awards Challenge. The Inspire Awards Challenge is hosted in collaboration with Solve—an initiative of the Massachusetts Institute of Technology (MIT), whose mission is to find and scale innovative solutions to global problems. From now until Aug. 7, 2026, qualifying nonprofits can submit applications through MIT Solve that answer this question: 

How are nonprofits providing innovative direct services, training programs, and career navigation supports for adult workers in the age of AI? 

"Artificial intelligence is transforming the way people learn, work and prepare for the future. We want to elevate organizations that are helping workers adapt with confidence and gain access to opportunities that support long term stability," said Lynette Bell, head of Truist Philanthropy and president of Truist Foundation. "The Inspire Awards program continues to spotlight nonprofits that are innovating to create meaningful change for individuals, families and communities as the world around them rapidly evolves."

Truist Foundation and MIT Solve will provide a six-month support and development program for a cohort of six nonprofit finalists to help transform ideas into actions and help finalists strengthen and scale their solutions. The program includes a comprehensive needs assessment, learning and development modules to help refine business plans, access to a network of resource partners and coaches, and more.

At the conclusion of the support program, all finalists will receive a grant to help implement their project. The first-place nonprofit will receive a $250,000 grant, second place will receive a $150,000 grant, and a $25,000 grant will be given to each runner-up team. New this year, a Community Choice Award will earn one finalist an additional $75,000 grant—regardless of their status as a first-place, second-place or runner-up grant recipient. 

"Nonprofits are helping workers adapt to a changing economy as AI reshapes every sector," said Hala Hanna, executive director of MIT Solve. "Through our collaboration with Truist Foundation, we are elevating solutions that expand opportunity and ensure that workers across industries can thrive in the age of AI. The Inspire Awards creates a powerful space for innovators to test and scale ideas that meet the real needs of communities."

The Truist Foundation Inspire Awards has become known as a space where nonprofits share and refine approaches that respond to community priorities around key economic mobility issues. Past finalists have contributed new ideas for career navigation, broadened access to training and credentialing, and helped workers pursue skills aligned with an evolving economy. The 2026-2027 program aims to build on this momentum by identifying organizations that are addressing the challenges and opportunities created by AI and emerging technologies.

To learn more or apply, click here.

About Truist Foundation
Truist Foundation is committed to Truist Financial Corporation's (NYSE: TFC) purpose to inspire and build better lives and communities. The Foundation, an endowed private foundation established in 2020 whose operating budget is independent of Truist Financial Corporation, makes strategic investments in a wide variety of nonprofit organizations centered around two focus areas: building career pathways to economic mobility and strengthening small businesses to ensure all communities have an equal opportunity to thrive. Embodying these focus areas are the Foundation's leading initiatives—the Inspire Awards and Where It Starts. Learn more at TruistFoundation.org.

SOURCE Truist Foundation

Local agencies, organizations, and associations are invited to collaborate with the EDGE Program, bringing financial educational opportunities to small business communities

, /PRNewswire/ -- The Acceleration Project (TAP), a nonprofit empowering under-resourced small business owners through high-impact consulting and mentorship, announced today the expansion of its Economic Development & Growth for Entrepreneurs (EDGE) Program for small business owners, with support from Truist Foundation. TAP was recently awarded a grant from Truist Foundation, which has provided the resources to bring this 2-year program, strengthening personal and business financial health, to 500 low to moderate-income small business owners across Florida, Georgia, North Carolina, Tennessee, South New Jersey, and Philadelphia.

Through no-cost coaching, small-group sessions, and one-on-one guidance, the EDGE program provides hands-on support to help small business owners build a stronger financial foundation. It is built around the Financial Health Network's FinHealth Score® framework, focusing on 4 key pillars - spending, saving, borrowing, and planning - to help entrepreneurs build stronger financial habits, improve long-term stability, and grow their businesses with confidence. At the end of each year in the program, 25 participants will receive monetary awards to invest in their businesses and help advance their goals. EDGE began in early 2026 in New York City and Westchester County, NY, with support from the Citi Foundation.

"The results we've seen thus far from small business owners participating in EDGE have been outstanding," said Jane Veron, CEO and Co-founder of TAP. "The knowledge and guidance they're gaining from our consultants teaching in this program are improving their financial confidence and decision-making skills. We're thrilled by the support of the Truist Foundation to expand this program to more states across the U.S., where small business owners are vital parts of communities and economies."

Applications to the expanded EDGE program for small business owners will open later this year. Community organizations, chambers of commerce, CFDIs, industry associations, city development agencies, nonprofits, and government entities that support the small business ecosystem are invited to join an informational session on June 24 or July 29 to learn more about the EDGE program, and how they can get involved and share the program with their own small business communities in August and September. Interested organizations can register for the June 24 session at 1:00pm ET linked here and the July 29 session at 12:00pm ET linked here.

"At Truist, our purpose is to inspire and build better lives and communities, and that comes to life through partnerships like this one. We're proud to support The Acceleration Project and its work to equip small business owners with the tools, guidance, and confidence they need to grow and thrive," said Truist Philadelphia market president Jeremy Ben-Zev. "Nonprofits like TAP play an important role in expanding opportunity, and we're honored to help advance that impact."

"Edge may have been the most organized and well-thought-out 1-on-1 I've had with TAP. My consultant was extremely helpful and professional," said Lee Hogans, Owner of WiLeeHo Music. "TAP continues to impress me by offering invaluable information through its consultants."

Questions or interest in the EDGE Program can be directed to [email protected]. Stay up-to-date on the EDGE program and find additional coaching and educational resources at https://www.theaccelerationproject.org.

About The Acceleration Project
The Acceleration Project (TAP) is a nonprofit organization that empowers under-resourced small business owners through high-impact consulting and mentorship. TAP supports small businesses nationwide across a wide range of industries with tailored guidance spanning finance, operations, marketing, and strategy, delivered at no cost to the small business owner. TAP has supported more than 11,900 businesses nationwide, helping small business owners achieve sustainable success, strengthen their communities, and expand economic mobility.

About Truist Foundation
Truist Foundation is committed to Truist Financial Corporation's (NYSE: TFC) purpose to inspire and build better lives and communities. The Foundation, an endowed private foundation established in 2020 whose operating budget is independent of Truist Financial Corporation, makes strategic investments in a wide variety of nonprofit organizations centered around two focus areas: building career pathways to economic mobility and strengthening small businesses to ensure all communities have an opportunity to thrive. Embodying these focus areas are the Foundation's leading initiatives – the Inspire Awards and Where It Starts. Learn more at Truistfoundation.org.

Media Contact:
[email protected]

SOURCE The Acceleration Project

ANDOVER, Mass., April 02, 2026 (GLOBE NEWSWIRE) -- Mercury Systems, Inc. (NASDAQ: MRCY, www.mrcy.com), a global technology company that delivers mission-critical processing to the edge, today announced it was awarded a contract from L3Harris Technologies (NYSE: LHX) to provide solid-state data recorders (SSDRs) for the U.S. Space Development Agency (SDA) Tranche 3 Tracking Layer satellite constellation.

L3Harris received a contract award in December to build 18 infrared satellites for the Tranche 3 Tracking Layer. These tracking layer satellites will enhance the SDA Proliferated Warfighter Space Architecture (PWSA) constellation that is designed to protect the United States from advanced missile threats, such as hypersonic missiles.

Mercury’s radiation-tolerant SSDRs are leveraged on all four tranches that L3Harris is developing for the PWSA Tracking Layer. Mercury recently completed delivery of SSDRs for all 18 of L3Harris’s Tranche 2 Tracking Layer satellites, after previously delivering data recorders for the Tranche 0 and Tranche 1 constellations.

With Tranche 3, L3Harris has moved to Mercury’s highest-capacity SSDR to date that delivers high performance and long-term data integrity in a 3U VPX form factor for space missions.

“Mercury is proud to support L3Harris to deliver a next-generation, layered defense architecture that can track missile threats in real time to protect our homeland,” said Ken Hermanny, Mercury’s Senior Vice President of Processing Technologies. “As the United States accelerates hardware production across all battlefield domains, Mercury is taking proactive measures to increase manufacturing capacity and efficiency in our operations.”

Mercury Systems – Innovation that matters® 
Mercury Systems is a global technology company that delivers mission-critical processing to the edge, making advanced technologies profoundly more accessible for today’s most challenging aerospace and defense missions. The Mercury Processing Platform allows customers to tap into innovative capabilities from silicon to system scale, turning data into decisions on timelines that matter. Mercury’s products and solutions are deployed in more than 300 programs and across 35 countries, enabling a broad range of applications in mission computing, sensor processing, command and control, and communications. Mercury is headquartered in Andover, Massachusetts, and has more than 20 locations worldwide. To learn more, visit mrcy.com. (Nasdaq: MRCY)

Forward-Looking Safe Harbor Statement 
This press release contains certain forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995, including those relating to the Company's focus on enhanced execution of the Company's strategic plan. You can identify these statements by the words “may,” “will,” “could,” “should,” “would,” “plans,” “expects,” “anticipates,” “continue,” “estimate,” “project,” “intend,” “likely,” “forecast,” “probable,” “potential,” and similar expressions. These forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. Such risks and uncertainties include, but are not limited to, continued funding of defense programs, the timing and amounts of such funding, general economic and business conditions, including unforeseen weakness in the Company’s markets, effects of any U.S. federal government shutdown or extended continuing resolution, effects of increasingly volatile geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, delays in or cost increases related to completing development, engineering and manufacturing programs, changes in customer order patterns, changes in product mix, continued success in technological advances and delivering technological innovations, changes in, or in the U.S. government’s interpretation of, federal export control or procurement rules and regulations, including tariffs, changes in, or in the interpretation or enforcement of, environmental rules and regulations, market acceptance of the Company's products, shortages in or delays in receiving components, supply chain delays or volatility for critical components, production delays or unanticipated expenses including due to quality issues or manufacturing execution issues, adherence to required manufacturing standards, capacity underutilization, increases in scrap or inventory write-offs, failure to achieve or maintain manufacturing quality certifications, such as AS9100, failure to achieve or maintain qualified business systems, such as those required by the DFARS, the impact of supply chain disruption, inflation and labor shortages, among other things, on program execution and the resulting effect on customer satisfaction, inability to fully realize the expected benefits from acquisitions, restructurings, and operational efficiency initiatives or delays in realizing such benefits, challenges in integrating acquired businesses and achieving anticipated synergies, effects of shareholder activism, increases in interest rates, changes to industrial security and cyber-security regulations and requirements and impacts from any cyber or insider threat events, changes in tax rates or tax regulations, changes to interest rate swaps or other cash flow hedging arrangements, changes to generally accepted accounting principles, difficulties in retaining key employees and customers, litigation, unanticipated costs under fixed-price service and system integration engagements, and various other factors beyond our control. These risks and uncertainties also include such additional risk factors as are discussed in the Company's filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended June 27, 2025 and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company cautions readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. The Company undertakes no obligation to update any forward-looking statement to reflect events or circumstances after the date on which such statement is made.

INVESTOR CONTACT
Tyler Hojo, CFA
Vice President, Investor Relations
[email protected]

MEDIA CONTACT
Turner Brinton
Senior Director, Corporate Communications
[email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f1ffd4fb-997f-4591-b49c-746ac6927d1e

Tranche 3 Tracking Layer L3Harris technology for the SDA Tranche 3 Tracking Layer program will provide infrared sensing, adva...